Clinical trials
Recherche d’études cliniques
Recherchez uniquement dans les études cliniques enregistrées dans Biomedical Watch.
Études cliniques 214
| Étude / NCT ⇅ | Molécule ⇅ | Maladie ⇅ | Phase ⇅ | Statut ⇅ | Résultat ⇅ | Sponsor ⇅ | Pays / centres ⇅ | Période ⇅ | Détail |
|---|---|---|---|---|---|---|---|---|---|
| NCT07266090 A Study to Evaluate the Safety,Tolerability,Pharmacokinetics and Pharma… |
Cenerimod 4 mg | Lupus | Phase 2 | ACTIVE_NOT_RECRUITING | En attente / non publié | Viatris Pharmaceuticals Co., Ltd. | China · First Affiliated Hospital of Henan University… | 2026-01-14 → 2027-10-08 | Ouvrir |
| NCT07732309 ATTRACT — A Study of ATG-201 in Adult Participants With Autoimmune Dise… |
ATG-201 | Lupus | Phase 1 | NOT_YET_RECRUITING | En attente / non publié | Antengene Biologics Limited | China · Huashan Hospital affiliated to Fudan Universi… | 2026-09-01 → 2029-06-01 | Ouvrir |
| NCT00756769 SLEIGH — Systemic Lupus Erythematosus in Gullah Health |
SLEIGH — Systemic Lupus Erythemat… | Lupus | À vérifier | RECRUITING | En attente / non publié | Medical University of South Carol… | United States · Medical University of South Carolina,… | 2003-04 → 2028-06 | Ouvrir |
| NCT07201558 ASSURO — Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in… |
Surovatamig | Lupus | Phase 1 | RECRUITING | En attente / non publié | AstraZeneca | United States, Australia, Belgium, Brazil, China, Ger… | 2025-12-02 → 2028-06-27 | Ouvrir |
| NCT03742037 Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in A… |
Cenerimod 0.5 mg | Lupus | Phase 2 | COMPLETED | En attente / non publié | Viatris Innovation GmbH | United States, Bulgaria, Chile, Czechia, France, Geor… | 2018-12-21 → 2022-08-25 | Ouvrir |
| NCT07201129 LUMIOS — A Research Trial to Assess if Cenerimod is Efficacious and Saf… |
Cenerimod | Lupus | Phase 3 | RECRUITING | En attente / non publié | Viatris Innovation GmbH | United States · Allied Biomedical Research Institute,… | 2026-02-09 → 2030-02 | Ouvrir |
| NCT04895696 A Study Evaluating the Efficacy and Safety of Afimetoran Compared With … |
Afimetoran | Lupus | Phase 2 | ACTIVE_NOT_RECRUITING | En attente / non publié | Bristol-Myers Squibb | United States, Argentina, Australia, Brazil, Chile, C… | 2021-10-11 → 2029-04-22 | Ouvrir |
| NCT05268289 Study of Efficacy and Safety of LNP023 in Participants With Active Lupu… |
Iptacopan (part 1) | Lupus | Phase 2 | RECRUITING | En attente / non publié | Novartis Pharmaceuticals | United States, Argentina, Brazil, China, Colombia, Fr… | 2022-08-10 → 2028-09-28 | Ouvrir |
| NCT05138133 IRIS — Phase 3 Study of Anifrolumab in Adult Patients With Active Proli… |
Anifrolumab | Lupus | Phase 3 | ACTIVE_NOT_RECRUITING | En attente / non publié | AstraZeneca | United States, Argentina, Belgium, Brazil, Bulgaria, … | 2022-02-15 → 2028-10-04 | Ouvrir |
| NCT06333483 CARLYSLE — Obe-cel in Adolescent [Applicable in UK Only] and Adult Seve… |
Obecabtagene autoleucel (obe-cel) | Lupus | Phase 1 | ACTIVE_NOT_RECRUITING | En attente / non publié | Autolus Limited | Spain, United Kingdom · Addenbrookes Hospital, Cambri… | 2024-02-02 → 2027-09 | Ouvrir |
| NCT05693571 ECHOS — Engagement in CHildhood-Onset Systemic Lupus |
ECHOS — Engagement in CHildhood-O… | Lupus | Non applicable | ACTIVE_NOT_RECRUITING | En attente / non publié | Montefiore Medical Center | United States · Montefiore Medical Center, The Bronx,… | 2024-12-05 → 2027-02 | Ouvrir |
| NCT07015983 A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T… |
CC-97540 | Lupus | Phase 2 | ACTIVE_NOT_RECRUITING | En attente / non publié | Juno Therapeutics, Inc., a Bristo… | United States, Argentina, Austria, Belgium, Brazil, C… | 2025-07-14 → 2032-06-15 | Ouvrir |
| NCT05869955 A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants … |
CC-97540 | Lupus | Phase 1 | ACTIVE_NOT_RECRUITING | En attente / non publié | Juno Therapeutics, Inc., a Bristo… | United States, Belgium, France, Germany, Italy, Spain… | 2023-09-13 → 2028-08-29 | Ouvrir |
| NCT07611214 PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifr… |
LUPKYNIS | Lupus | Phase 4 | RECRUITING | En attente / non publié | Aurinia Pharmaceuticals Inc. | United States · Accurate Clinical Research, Inc., Lak… | 2026-04-22 → 2029-03-02 | Ouvrir |
| NCT06044337 AMETHYST LTE — A Long-Term Extension Study to Learn More About the Safe… |
BIIB059 (litifilimab) | Lupus | Phase 3 | ENROLLING_BY_INVITATION | En attente / non publié | Biogen | United States, Argentina, Brazil, Bulgaria, Canada, C… | 2023-10-03 → 2029-12-11 | Ouvrir |
| NCT05567198 Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation … |
Gonadotropin-releasing Hormone Ag… | Lupus | À vérifier | RECRUITING | En attente / non publié | National Institute of Arthritis a… | United States · National Institute of Arthritis and M… | 2023-03-03 → 2027-05-31 | Ouvrir |
| NCT06419205 A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity o… |
ADX-097 | Lupus | Phase 2 | RECRUITING | En attente / non publié | Akebia Therapeutics | United States, Brazil · Investigator Site #1, Lawrenc… | 2026-07-30 → 2028-02 | Ouvrir |
| NCT05799378 SHIELD — Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease |
Hydroxychloroquine | Lupus | Phase 3 | RECRUITING | En attente / non publié | NYU Langone Health | United States · Columbia University Irving Medical Ce… | 2024-06-27 → 2029-06-30 | Ouvrir |
| NCT06984341 A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharma… |
P-CD19CD20-ALLO1 Cells | Lupus | Phase 1 | WITHDRAWN | En attente / non publié | Genentech, Inc. | United States · University of Alabama at Birmingham: … | 2026-06-30 → 2033-11-01 | Ouvrir |
| NCT05039619 POSTERITY — A Study to Evaluate the Efficacy, Safety, and Pharmacokinet… |
Obinutuzumab | Lupus | Phase 2 | RECRUITING | En attente / non publié | M.D. Anderson Cancer Center | United States, Brazil, Canada, France, Italy, Mexico,… | 2022-05-12 → 2030-06-14 | Ouvrir |
| NCT05039840 APATURA — Efficacy and Safety of Frexalimab (SAR441344) in the Treatmen… |
SAR441344 IV | Lupus | Phase 2 | ACTIVE_NOT_RECRUITING | En attente / non publié | Sanofi | United States, Argentina, Brazil, Chile, Georgia, Gre… | 2021-11-10 → 2026-11-24 | Ouvrir |
| NCT07409181 A Study to Test Whether Different Doses of BI 3000202 Help People With … |
BI 3000202 | Lupus | Phase 2 | RECRUITING | En attente / non publié | Boehringer Ingelheim | United States, Argentina, Australia, Brazil, Bulgaria… | 2026-04-20 → 2029-07-08 | Ouvrir |
| NCT07749430 A Clinical Study of ACG102 Injection in Patients With Refractory Active… |
ACG102 Injection | Lupus | Phase 1 | NOT_YET_RECRUITING | En attente / non publié | Union Hospital, Tongji Medical Co… | Non communiqué | 2026-09-15 → 2028-01-30 | Ouvrir |
| NCT06617325 PHOENYCS FLY — A Study to Evaluate the Efficacy and Safety of Dapiroliz… |
DZP | Lupus | Phase 3 | RECRUITING | En attente / non publié | UCB Biopharma SRL | United States, Argentina, Belgium, Canada, Chile, Chi… | 2024-11-21 → 2028-05-31 | Ouvrir |
| NCT07751315 A Study of QLS2404 Injection in Healthy Participants and Participants W… |
Ia:QLS2404 very low dose | Lupus | Phase 1 | NOT_YET_RECRUITING | En attente / non publié | Qilu Pharmaceutical Co., Ltd. | China · West China Hospital of Sichuan University, Ch… | 2026-08-11 → 2028-06-30 | Ouvrir |